Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2023-11-15 00:00:00 ET · period of report 2023-11-13 · accession 0000875320-23-000035 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-11-15 | 2023-11-13 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | S - Sale | $377.00 | -5,097 | 113.8K | -4% | -$1.92M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-13 | S | D | 5,097 | $377.00 | 113,809 | D | — | — |